Neuland Labs announces a $30mn investment to expand its global Peptide production capabilities
Neuland Labs achieved an outstanding ESG Score of 70/100 from S&P Global Sustainable 1
Neuland Labs proudly announces its new Vision and Values statements
Neuland Labs has been recognised as the ‘Top Value Creator’ in the Pharmaceutical Industry by Dun & Bradstreet India for delivering long-term value to all their stakeholders beyond financial growth
Neuland Labs has been honoured with the prestigious Sword of Honour by the British Safety Council
Securing Sustainability Throughout the Pharmaceutical Supply Chain SUCHETH DAVULURI Vice Chairman and CEO
Neuland Labs' Manufacturing Unit III Facility secured a Five Star Safety Rating with an audit score of 92.29% from the British Safety Council
Neuland Labs' Manufacturing Unit II Facility achieved a Five Star Safety Rating with an audit score of 92.20% from the British Safety Council
Neuland unveils its dynamic new brand identity reinforcing its commitment to agility, ethics, partnerships, and growth
Our Vice-Chairman and CEO, Sucheth Davuluri, takes the global stage on Sustainability at the #DCATs’ first European Global Bio/Pharmaceutical Sustainability Summit in Lugano, Switzerland
Unit I Manufacturing facility of Neuland Labs successfully passed the USFDA audit yet again with nil 483 observations in March 2024 which signifies compliance and conformance to applicable Current Good Manufacturing Practice (cGMP) regulations enforced by the USFDA
Neuland Labs has been recognized by S&P Global Sustainable1 with a noteworthy rating of 64 out of 100 for its commitment to ESG practices and honoured to be among the 6 Indian companies in the Pharma/Biotech/Lifesciences services domain to be selected for the prestigious S&P Sustainability Yearbook 2024!
Neuland has been awarded a ‘Silver Medal’ from EcoVadis in recognition of its Sustainability achievements
